Pfizer's Change Management: Unfamiliar Faces
Executive Summary
The dust at Pfizer still hasn't settled as new CEO Jeff Kindler shakes up the senior office suite at the world's largest pharmaceutical company. But the dust hasn't obscured the basic message: Pfizer's strategic and managerial model hasn't worked. What's more, the Big Pharma's board is one of a handful in the industry coming to similar conclusions.
You may also be interested in...
New Management in Pharma: Insiderism
Big Pharma is under the gun, with plenty of top management changes. By early next year, the industry will have seen five new CEOs; five new CFOs; a handful of changes in the top R&D spots, and a couple of new commercial bosses, all announced since the beginning of 2007 (an exhibit charts the changes). Of the sixteen job changes, six came about because the predecessor in the job was, if not outright fired, at least pressured to leave. But how much change are we really going to see?
The Heyday of Biotech Dealmaking
Deal values and perks are up for biotechs; the Pharmaceutical Strategic Outlook conference suggests Big Pharma might begin to borrow some biotech strategies.
The Heyday of Biotech Dealmaking
Deal values and perks are up for biotechs; the Pharmaceutical Strategic Outlook conference suggests Big Pharma might begin to borrow some biotech strategies.